Your session is about to expire
← Back to Search
Hormonal Therapy for Breast Cancer
Study Summary
This trial will study the effects of a short-term hormone therapy on the genes and molecules of breast cancer patients.
- Breast Cancer
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have previously received hormonal therapy, chemotherapy, radiation therapy, or new treatments for your current breast cancer.You are allergic to tamoxifen, letrozole, or exemestane, or any of the ingredients in these medications.
- Group 1: Exemestane arm
- Group 2: Tamoxifen arm
- Group 3: Letrozole arm
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is there an age limit for applicants to this medical experiment?
"All applicants for this medical trial need to be aged between 18 and 90. There are 85 sub-18 year old trials available and 2680 studies targeting those over 65 years of age."
Is there capacity for more participants to join this clinical research?
"Unfortunately, this trial is no longer in search for participants. It was initially posted on February 20th 2019 and modified on November 11th 2022. A number of other studies are still enrolling patients with breast cancer (2596) as well as 204 trials associated with Blueprint that remain open to potential volunteers."
Can I become a participant in this experiment?
"30 suitable candidates, aged 18 to 90 and presenting with breast cancer, are being sought for enrollment. Criteria include: never having received treatment; displaying histologically confirmed invasive ductal carcinoma between stages 1-3; co-enrollment in the FLEX Registry; ER+/PR+ hormone receptor statuses defined by immunohistochemistry (IHC); capability of comprehending their condition and giving informed consent."
What other investigative studies have been conducted concerning Blueprint's efficacy?
"Currently there are 204 clinical trials delving into Blueprint, with 57 of them in the final phase. Most of these experiments take place in San Francisco but can be found at 13123 sites around America."
For what maladies is Blueprint typically utilized?
"Blueprint is a proven treatment for polycystic ovary syndrome and can additionally be beneficial in managing breast cancer, post-breast surgery recovery, and other mammary complications."
What is the primary objective of this medical experiment?
"The primary goal of this research, which will be evaluated at Baseline and up to 6 weeks post-surgery, is the alteration in Ki67 expression as assessed by immunohistochemistry. Secondary objectives include an evaluation of Mammaprint risk report (high or low chance of recurrence), single gene read out measuring Estrogen Receptor protein concentrations (>10% for positive/ <1% for negative) , as well as Estrogen Receptor protein amounts using Immunohistochemistry."
What potential hazards might patients be exposed to when taking Blueprint?
"Although there is a collection of data indicating the safety of Blueprint, no evidence exists to confirm its efficacy. As such, it received a rating 2 on our team's scale from 1 to 3."
What is the accepted participant capacity of this experiment?
"This clinical trial has concluded its recruitment period. First posted on February 20th 2019, the study was last updated November 11th 2022. If you are seeking other studies, 2596 trials for breast cancer and 204 Blueprint related ones presently require participants."
Share this study with friends
Copy Link
Messenger